La dernière actualité médicale HaemophiliaXPERT
Consultez la version en ligne
HaemophiliaXPERT
Chère consœur, cher confrère,
Retrouvez ci-après les dernières publications scientifiques issues de revues à comité de lecture dans votre domaine d'expertise.
Publications du Mardi 16 juin 2026
Inhibitor development according to FVIII concentrates in PUPs with severe hemophilia A: update from the PedNet registry
Journal of Thrombosis and Haemostasis 2026; AOP:10.1016/j.jtha.2026.04.031
Treatment of severe Hemophilia A (SHA) with FVIII concentrates is complicated by development of neutralizing inhibitors in about 30% during the first 50 exposure days (EDs). Despite extensive research,...
En savoir plus |  Version PDF  |  Imprimer l'abstract
UK Experience of Children With Inhibitors in Severe Haemophilia B: A Report by the UKHCDO Paediatric Working Party.
Haemophilia (2026).
The development of neutralising antibodies (inhibitors) against FIX is the most serious complication of treatment in severe haemophilia B (SHB), and given the overall rarity of inhibitor formation (5%-10%),...
En savoir plus |  Version PDF  |  Imprimer l'abstract
Biomarkers as Diagnostic and Prognostic Tools for Hemophilic Arthropathy.
Hamostaseologie 2026 May
Repeated joint bleeds cause hemophilic arthropathy, which can develop despite regular prophylaxis with clotting factors. Therefore, recognizing ongoing or subclinical bleeds is an important element of...
En savoir plus  |  Free Full-text
Hemophilia in the Era of Advanced Therapies: Structural Monitoring, the Role of Musculoskeletal Ultrasound, and a Proposed Multidisciplinary Care Model-A Structured Narrative Review.
Diagnostics (Basel, Switzerland) 2026 May; 16(11)
Advances in hemophilia treatment, including extended half-life factor concentrates, non-replacement therapies, and gene therapy, have substantially reduced bleeding frequency and improved life expectancy....
En savoir plus  |  Free Full-text
LFB
Accueil  |  Actualités  |  Archives
Informer un confrère | Modifier votre profil | Se désinscrire | Sources et critères
GNM Healthcare